Sahajanand Medical Technologies
No DCF model value for Sahajanand Medical Technologies yet.
A model value is not currently available for this company.
All values are mathematically derived from financial models and do not constitute buy, sell, or hold recommendations. Models rely on historical data and assumptions that may not reflect future outcomes. StockRank is not a registered investment advisor — always do your own research before making investment decisions.
360° view
The takeaway
A profitable medical-device maker with moderate leverage and solid cash conversion, but its high earnings multiples and thin data coverage leave the investment profile only partly evidenced.
↗ Strengths
- Reported operating margin was 14% and net margin 5.7%, with return on capital employed of 13.29% and a five-year median of 11.61%.
- Interest coverage was 7.32x, debt-to-equity 0.39 and the current ratio 1.65, indicating moderate leverage and adequate near-term liquidity.
- Operating cash flow covered reported net profit 1.61 times, and the Piotroski score was 6 of 9.
↘ Risks to watch
- Growth and price-performance inputs are unavailable, so the record cannot support a complete five-axis assessment; the overall score reflects only three observed areas.
- The P/E is 83.1x and EV/EBITDA 33.0x on the supplied annual figures, while the DCF valuation model result is unavailable.
- Promoter holding and pledge data are missing, so ownership concentration and pledging cannot be assessed.
Sahajanand Medical Technologies manufactures and distributes Class III and Class C/D medical devices, including coronary stents and balloons for vascular intervention, structural heart products such as trans-catheter aortic valves and occluders, and peripheral and renal devices. It also trades and distributes surgical, hospital, pharmaceutical, dental, laboratory and orthopaedic products. Operations span India, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Available descriptions differ on the founding year and headquarters location, and reported revenue-segment detail is too ambiguous to describe the revenue mix.
Key metrics
Latest reported · price-based figures use the EOD quote5 scoring axes
How cheaply the stock is priced relative to earnings, assets, and cash flows vs peers.
33/100How cheaply the stock is priced relative to earnings, assets, and cash flows vs peers.
- Market value of equity relative to reported shareholder equity. Asset quality, profitability and accounting practices affect how the ratio should be read.
- 7.80×
- Market value of equity relative to the latest annual common earnings. It uses an annual period rather than the trailing 12 months and can be affected by one-off earnings.
- 83.14×
- P/E divided by the earnings-growth rate used in the ratio. Its meaning depends on that growth period and whether growth is sustainable.
- —
- Enterprise value relative to the latest annual earnings before interest, tax, depreciation and amortisation. It includes debt in valuation but does not account for capital spending or all cash needs.
- 32.98×
- Reported annual operating cash flow as a percentage of current market value of equity. This is before capital spending, so it is not free cash flow.
- 1.94%
- Percentage difference between the saved valuation estimate and its reference share price. It depends on assumptions and is not a forecast return.
- —
Profitability, capital efficiency, and consistency of cash generation.
54/100Profitability, capital efficiency, and consistency of cash generation.
- Net profit as a percentage of revenue for the latest annual period. Tax, financing and one-off items can affect the margin.
- 5.70%
- Operating profit as a percentage of revenue for the latest annual period. It reflects operating profitability before financing and tax, and varies by industry.
- 14.00%
- A count of nine accounting checks covering profitability, financial position and operating efficiency. More checks passed does not guarantee future performance, and the measure is less suited to financial businesses.
- 6 / 9
- Operating profit relative to the capital used in the business. It indicates capital efficiency, but industry capital needs and accounting values affect comparisons.
- 13.29%
- Net profit relative to shareholder equity. Debt or a small equity base can raise this ratio without improving the underlying business.
- 9.38%
- Operating cash flow divided by common net profit for the same annual period. It shows how earnings translate into operating cash, but working-capital timing can move the ratio.
- 1.61×
- The share of observed annual periods with positive common earnings within the last ten years. It describes profit frequency, not the size or stability of those profits.
- 66.67%
- The middle annual return on capital employed from the five-year history. It reduces the influence of a single unusual year but can hide recent changes.
- 11.61%
Revenue and earnings growth rates across multiple time horizons.
—/100Revenue and earnings growth rates across multiple time horizons.
- Operating cash flow growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- —
- Earnings-per-share growth expressed as a compounded annual rate over three years. Changes in share count and one-off profits can affect the rate.
- —
- Net profit growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- —
- Net profit growth expressed as a compounded annual rate over 5 years. It smooths year-to-year changes and does not predict future growth.
- —
- Revenue change from the same quarter a year earlier. It reduces seasonal differences, but a weak comparison period can amplify growth.
- —
- Revenue growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- —
- Revenue growth expressed as a compounded annual rate over 5 years. It smooths year-to-year changes and does not predict future growth.
- —
Balance sheet strength, leverage, and financial stability.
40/100Balance sheet strength, leverage, and financial stability.
- Cash and cash equivalents divided by borrowings. It shows how much borrowing is covered by reported cash, which may not all be freely available.
- 0.28×
- Current assets divided by current liabilities. It describes short-term balance-sheet coverage, but inventories and receivables may not turn into cash quickly.
- 1.65×
- Borrowings relative to shareholder equity. More borrowing can increase financing risk; the ratio has different meaning for lenders and is not useful with nonpositive equity.
- 0.39×
- Earnings available to cover interest expense, expressed as a multiple. It indicates interest-payment capacity but does not cover principal repayments or all cash needs.
- 7.32×
- The share of promoter holdings pledged as collateral. Pledging can create financing pressure if collateral values fall; zero pledging does not remove other risks.
- —
- The percentage of shares held by promoters. Ownership concentration can align interests but does not by itself establish governance quality.
- —
Recent price moves and changes in earnings and institutional ownership.
—/100Recent price moves and changes in earnings and institutional ownership.
- Change in the share of equity held by domestic institutional investors over one year, in percentage points. It describes ownership changes, not the cash they invested or future returns.
- —
- The latest quarterly operating margin minus the average of the preceding four quarters, in percentage points. It describes a margin change, not percentage growth in profit.
- —
- Net profit change from the same quarter a year earlier. One-off items and a small comparison-period profit can make the percentage unusually large.
- —
- Revenue change from the same quarter a year earlier. It reduces seasonal differences, but a weak comparison period can amplify growth.
- —
- Share-price change over one year. Past price performance does not predict future returns.
- —
- Share-price change over three years in total, not per year. Past price performance does not predict future returns.
- —
Quarterly Results
₹ Cr · per share in ₹| Particulars | Jun '26 | Sep '26 |
|---|---|---|
| − Revenue | ||
| Revenue | 351.67 | 373.41 |
| − Profitability | ||
| Operating Profit | 48.58 | 65.55 |
| OPM % | 13.81% | 17.56% |
| Profit Before Tax | 24.28 | 40.07 |
| − Bottom Line | ||
| Net Profit | 14.57 | 25.79 |
| EPS | 1.48 | 2.63 |
Income Statement
Annual · ₹ Cr · per share in ₹| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| − Revenue | |||
| Revenue | 901.60 | 1,024.88 | 1,210.50 |
| Revenue Growth | — | 13.67% | 18.11% |
| − Expenses & Profitability | |||
| Operating Profit | 110.05 | 128.02 | 170.66 |
| OPM % | 12.11% | 12.36% | 14.00% |
| Profit Before Tax | 33.09 | 40.81 | 80.29 |
| − Bottom Line | |||
| Net Profit | -12.77 | 20.36 | 65.28 |
| Profit Growth | — | — | 220.63% |
| EPS | -1.31 | 2.09 | 6.67 |
Balance Sheet
Annual · ₹ CrLiabilities shown exclude shareholders’ funds and other equity. Assets equal liabilities plus equity.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| − Equity | |||
| Shareholders' Funds | 540.08 | 565.73 | 695.46 |
| − Liabilities | |||
| Total Borrowings | 175.27 | 224.96 | 269.52 |
| Total Current Liabilities | 350.79 | 435.82 | 488.79 |
| Total Liabilities | 404.26 | 504.43 | 574.14 |
| − Assets | |||
| Fixed Assets | 264.11 | 247.76 | 302.91 |
| Investments | 6.30 | 4.92 | 58.55 |
| Cash & Equivalents | 73.53 | 101.84 | 75.48 |
| Total Current Assets | 596.40 | 698.71 | 808.78 |
| Total Assets | 970.58 | 1,094.90 | 1,276.43 |
Cash Flow
Annual · ₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| − Cash Flows | |||
| Cash from Operations | 41.10 | 73.52 | 105.19 |
| Cash from Investing | -42.47 | -48.94 | -130.03 |
| Cash from Financing | 13.13 | 5.77 | -12.04 |
| Net Cash Flow | 12.43 | 28.85 | -26.43 |
| − Cash Position | |||
| Closing Cash | 71.67 | 100.52 | 74.09 |
Shareholding Pattern
Promoters hold 36.2% of Sahajanand Medical Technologies, the largest share.
| Holder | 22 Oct ’26 |
|---|---|
| Promoters | 36.2% |
| Foreign institutions FII | 35.1% |
| Indian institutions DII | 11.8% |
| Public | 13.4% |
| Others | 3.5% |
Darker shading marks the quarters when that holder owned more.
Dividend History
No dividends are on record for Sahajanand Medical Technologies.




